NEW YORK, Jan. 27, 2011 /PRNewswire/ -- Get content from AstraZeneca at:
Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the full year was unchanged at constant exchange rates (CER) at $33,269 million. Strong revenue growth in markets outside the US (up 7% at CER) broadly offset the loss of more than $1.6 billion of revenue in the US from generic competition on several products and the absence of H1N1 pandemic influenza vaccine revenue. Strong double-digit sales growth at CER for Crestor, Symbicort and Seroquel XR. Crestor and Seroquel franchise sales now exceed $5 billion each for the full year. Revenue in Emerging Markets grew to over $5.1 billion, a 16% increase at CER. China increased to over $1.0 billion in annual revenue. Core operating profit for the full year unchanged at CER at $13,603 million. Core EPS for the full year increased by 5% at CER to $6.71. Available video includes headquarters, laboratory and production shots.
About thenewsmarket.com
thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE, ZDF and a lot more.
Registered journalists can preview and download video, audio, text, graphics and photos at http://www.thenewsmarket.com.
If not already registered, please take a moment to sign up - registration is quick, easy and free: http://www.thenewsmarket.com/registration
We are always happy to receive your feedback, suggestions or enquiries. Email us at [email protected]
Story Id: 21372
SOURCE thenewsmarket.com